EN
CPHI Barcelona 2023: SINOVAC Showcases Comprehensive Product Portfolio
Pioneering Antibody Products and WHO Approved Vaccines Will Advance Prevention and Treatment of Infectious Diseases
October 19, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, will showcase groundbreaking products and an extensive portfolio targeting various infectious diseases at CPHI Barcelona 2023, Booth 1D41 (Zone FDF), from October 24 to 26.
Notably, SINOVAC will debut the Antibody SA55 Injection and Nasal Spray, based on an innovative broad-spectrum neutralizing antibody that advances the treatment and prevention of COVID-19. Recent studies shows these products’ efficacy in neutralizing the omicron variant and its sublineages, including BA.5, BF.7, BQ.1.1, XBB.1.5, BA.2.86 and EG.5.
In addition to these innovative antibody products, SINOVAC will showcase:
· World Health Organization (WHO) prequalified vaccines, including Healive® for hepatitis A; PROVARIX for varicella; and a vaccine for Sabin-strain inactivated polio.
· Highly protective trivalent influenza vaccine, Anflu®, and quadrivalent influenza vaccine, TetrAnflu.
· World-leading enterovirus type 71 vaccine, Inlive®.
· CoronaVac®, one of the most widely administered COVID-19 vaccines globally and the only inactivated COVID-19 vaccine approved for children as young as 6 months old.
"While the WHO has declared an end to the global health emergency caused by COVID-19, the world is still facing the threat of various infectious diseases in 2023," said Ms. Helen Yang, Chief Business Officer of SINOVAC. "As a leading biopharmaceutical product provider in China, SINOVAC remains committed to increasing our investment in R&D, vaccine production and the exploration of cutting-edge biomedical products, including antibodies. It is the right time to introduce our most recent innovations and explore opportunities for international collaboration that aids in our mission to 'Supply Vaccines to Eliminate Human Diseases'."
Discover SINOVAC's comprehensive product portfolio at CPHI Barcelona 2023
Explore SINOVAC's comprehensive portfolio of products and technologies and meet with SINOVAC experts onsite at Booth 1D41 (Zone FDF) or contact Alice Chen via info@sinovac.com to schedule a personalized engagement.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.
SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.
SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.
With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.
For more information, please see the Company's website at www.sinovac.com.